Generics manufacturer Actavis has launched rabeprazole gastro-resistant tablets in 10mg and 20mg doses, following patent expiry.
The tablets are indicated for active duodenal or active benign gastric ulcers and several forms of gastro-oesophageal reflux disease. Rabeprazole gastro-resistant tablets can also be used to treat Zollinger-Ellison syndrome and, with antibiotics, to eradicate Helicobacter pylori in peptic ulcer disease.
Actavis said the product was its fourth in this therapy area, joining pantoprazole, lansoprazole and omeprazole.
A 28-tablet box of the 10mg dose is priced at £3.47, while a packet of the 20mg dose is £5.87.
Call 0800 731 0370 for more information